Loading
A phase 1 trial of LTZ-232 run by LTZ Therapeutics, Inc., now recruiting.
This is a Phase 1/1b Study to Evaluate the Safety and Preliminary Antitumor Activity of LTZ-232 in Participants With Advanced/Metastatic Colorectal Cancer and Other Solid Tumors is a phase 1 interventional study registered as NCT07878988 by LTZ Therapeutics, Inc., with 152 participants planned, started 2026-10-28. Conditions recorded: Colorectal Cancer, Advanced/Metastatic Solid Tumor, Solid Tumor (Phase I), EPCAM and Colon Cancer. Interventions recorded: LTZ-232.
Shares LTZ Therapeutics and the tag pipeline.
Shares LTZ Therapeutics and the tag pipeline.
Shares Colon cancer (adenocarcinoma of the colon), Colorectal cancer and the tag pipeline.
Shares Metastatic cancer (cancer that has spread), Colorectal cancer and the tag pipeline.
Shares Metastatic cancer (cancer that has spread), Colorectal cancer and the tag pipeline.
Shares Colon cancer (adenocarcinoma of the colon), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread), Colorectal cancer and the tag pipeline.
Shares Metastatic cancer (cancer that has spread), Colorectal cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/